Balchem Dividends and Buybacks
Dividend criteria checks 0/6
Balchem is a dividend paying company with a current yield of 0.59%.
Key information
0.6%
Dividend yield
2.0%
Buyback Yield
| Total Shareholder Yield | 2.6% |
| Future Dividend Yield | 0.8% |
| Dividend Growth | 10.3% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 20% |
Recent dividend and buyback updates
Recent updates
Balchem: An Attractive Valuation Makes This Stock A Buy
Mar 27
Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential
Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist
Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?
BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns
Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
Feb 15
BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns
Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?
Feb 01BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns
Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns
Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns
Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.BCPC: Share Repurchases Will Support Attractive Long Term Return Potential
Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital
Dec 01Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio
Oct 10Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Sep 26Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Aug 26Balchem (NASDAQ:BCPC) Is Looking To Continue Growing Its Returns On Capital
Jul 21These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Safely
Jun 23When Should You Buy Balchem Corporation (NASDAQ:BCPC)?
May 26Estimating The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)
May 12Balchem's Q3 Shows Record Earnings And Valuation Pressure
Oct 28
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Balchem: A Tale Of Two Businesses
May 10Balchem: Potential Turnaround Is In The Price
Feb 21Stability and Growth of Payments
Fetching dividends data
Stable Dividend: BCPC is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: BCPC is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Balchem Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BCPC) | 0.6% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Chemicals) | 1.7% |
| Analyst forecast (BCPC) (up to 3 years) | 0.8% |
Notable Dividend: BCPC's dividend (0.59%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.4%).
High Dividend: BCPC's dividend (0.59%) is low compared to the top 25% of dividend payers in the US market (4.23%).
Earnings Payout to Shareholders
Earnings Coverage: BCPC is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: BCPC is not paying a notable dividend for the US market.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/01 04:08 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Balchem Corporation is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |